After a patient is diagnosed with breast cancer, doctors and patients work together to plan the best course of treatment. Along with other pieces of information, the OncotypeDX® Breast Recurrence Score Test can assist in deciding whether or not to make chemotherapy part of their treatment plan. The test can also help doctors determine the likelihood of the cancer returning in the future, also known as recurrence.
The OncotypeDX® Breast Recurrence Score Test works by examining a sample of breast cancer tissue. The test measures a group of breast cancer genes in this sample to see how active they are (also known as how they are expressed). The result of the test is reported as a number between 0 and 100, known as the Recurrence Score result. A lower score means the cancer has a lower chance of returning, and a higher score means that there is a higher chance of the cancer returning. The score also provides patients and doctors with important information regarding the potential benefit of adding chemotherapy to hormonal therapy. A low score indicates that the patient will receive minimal benefit from chemotherapy, whereas a patient with a high score can have significant benefit from chemotherapy. Because everyone's body and tumor are unique, obtaining a Recurrence Score result helps make treatment decisions tailored to the patient.
The OncotypeDX® Breast Recurrence Score Test provides information in addition to standard measurements (such as tumor size, tumor grade and lymph node status) that doctors have traditionally used to estimate how likely a patient's cancer is to return, and to help make treatment decisions.
The Oncotype DX® Breast Recurrence Score Test has been validated and provides level 1, category B evidence as defined by Simon et al. Consistent results across multiple well-designed studies demonstrate the assay’s robust analytic performance, clinical validity and clinical utility. As a result the assay has been incorporated into multiple guidelines including National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), National Institute for Health and Care Excellence (NICE), St. Gallen, and European Society for Medical Oncology (ESMO).
For more information please visit Oncotype DX®.
Genomic Health, Inc. (now trading as "Exact Sciences")
Oncotype DX Breast Recurrence Score, Oncotype DX and Recurrence Score are registered trademarks of Genomic Health, Inc.
Exact Sciences is a trademark or registered trademark of Exact Sciences Corporation. ©2020 Genomic Health, Inc. All rights reserved.
The expected TAT of the OncotypeDX® Breast Recurrence Score test results is up to 10 working days. (Greece, Cyprus, Romania & Turkey)